Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin c and hiprex: a new hope against recurring UTIs?

NCT ID NCT06710899

Disease control Sponsor: University Hospitals of North Midlands NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether adding vitamin C to the drug methenamine hippurate (Hiprex) helps prevent recurrent urinary tract infections (UTIs) in women. Twenty women will take either Hiprex alone or Hiprex plus vitamin C for six months each, and researchers will compare how many UTIs occur. The goal is to see if this simple combination works better than the drug alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methenamine hippurate (Hiprex) with or without vitamin C
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent recurrent urinary tract infections in women.
What could go wrong
This is a very early, small proof-of-concept study with only 20 participants. It may not show a clear benefit, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female * Age ≥18 years * Recurrent proven UTI, defined as "two or more proven infections in six months or three or more infections in six months" * Willing and able to give fully informed consent * Patients suitable for prophylaxis following discussion with their clinician. * No contra-indications to treatment with methenamine hippurate or Vitamin C * All women will have undergone standard diagnostic work-up and have followed routine conservative UTI prevention measures. * A working email address to be used to submit urine pH results * Willing and able to comply with the study procedures * Females of childbearing potential must be willing to use a highly effective method of contraception (hormonal or barrier method of birth control; abstinence; sterilisation or vasectomised partner) Exclusion Criteria: * Males * Women who are pregnant or breast-feeding * Contraindications to methenamine hippurate as described in BNF: known allergy, gout, severe metabolic acidosis, severe dehydration, eGFR less than 10 ml/min, severe hepatic impairment * Currently using vitamin C containing supplement or cranberry extract tablets * Women using urinary alkalinisation agents, e.g potassium citrate, sodium bicarbonate * Currently receiving any form of bladder instillation or intradetrusor Onabotulinum Toxin A injections * Patients already on low-dose antibiotics or methenamine hippurate (due to delay that will be incurred by 3-month washout period) * Indwelling urinary catheter in situ or performing clean intermittent self-catheterisation * Correctable urinary tract abnormalities, e.g., urinary tract calculi, urinary retention * Formation of ileal conduit or augmented bladder * Neurogenic bladder dysfunction * Hyperoxaluria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent urinary tract infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary tract infection urinary tract infections, recurrent, susceptibility to

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Urinary tract infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals of North Midlands NHS Trust

    Stoke-on-Trent, Staffordshire, ST4 6QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.